UPCOMING Rx-TO-OTC SWITCH REVIEWS PROVIDE NEEDED GOOD NEWS FOR DRUG STOCKS
This article was originally published in The Tan Sheet
Executive Summary
UPCOMING Rx-TO-OTC SWITCH REVIEWS PROVIDE NEEDED GOOD NEWS FOR DRUG STOCKS in the second quarter of 1994, contributing to gains made by Johnson & Johnson (up 13,6% on a 5-1/8-point gain to 42- 7/8) and SmithKline Beecham (up 12.5% on a 3-1/8-point increase to 28-1/8). J&J/Merck's Rx-to-OTC switch NDA for Pepcid (famotidine) is scheduled to be reviewed by FDA's Nonprescription Drugs and Gastrointestinal Drugs Advisory Committees on July 29 while SmithKline Beecham's switch application for Tagamet is set to be revisited by the committees on July 27 ("The Tan Sheet" June 27, p. 1).